Fewer than a tenth of people that would benefit from weight-loss injections including Wegovy have access to them, states the World Health Organization as it publishes its initial advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging increased and just access to this class of drugs.
According to estimates, over two billion are projected to be living with obesity by 2030 unless action is taken.
"The new guidelines acknowledges that obesity is a long-term condition that can be treated with thorough and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant hurdles to universal availability to the jabs that can aid individuals in losing considerable body mass, explains the body.
Weight-Loss Drug Supply Crisis
Even in the present most optimistic scenario, the production of GLP-1 therapies could only cover about 100 million people – fewer than 10% of eligible patients, per the health organization.
The advice calls on nations and manufacturers to increase access, through strategies like licensing agreements.
The intellectual property rights on the active ingredient – the core component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Drugs Work
GLP-1 drugs imitate a natural hormone to reduce digestion speed, suppress the appetite and increase the sense of being full so users reduce food intake.
People usually start to lose weight after several weeks of starting on the regular doses.
Research indicates users may regain a significant portion after a year of discontinuing the treatment, as their normal appetite return.
Being overweight or obese raises your risk for contracting health problems, like type 2 diabetes, heart disease, stroke, and certain malignancies.
Obesity concerns individuals in every country and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
